Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
46.1M
-
Number of holders
-
92
-
Total shares
-
30.4M
-
Shares change
-
+2.41M
-
Total reported value, excl. options
-
$522M
-
Value change
-
+$35M
-
Put/Call ratio
-
1.35
-
Number of buys
-
52
-
Number of sells
-
-38
-
Price
-
$17.19
Significant Holders of 4D Molecular Therapeutics, Inc. - Common Stock, $0.0001 par value per share (FDMT) as of Q1 2023
96 filings reported holding FDMT - 4D Molecular Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q1 2023.
4D Molecular Therapeutics, Inc. - Common Stock, $0.0001 par value per share (FDMT) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.4M shares
of 46.1M outstanding shares and own 65.93% of the company stock.
Largest 10 shareholders include BVF INC/IL (4.01M shares), VIKING GLOBAL INVESTORS LP (3.94M shares), BlackRock Inc. (2.55M shares), Deep Track Capital, LP (2.28M shares), STATE STREET CORP (2.04M shares), JANUS HENDERSON GROUP PLC (1.88M shares), MORGAN STANLEY (1.74M shares), VANGUARD GROUP INC (1.55M shares), Casdin Capital, LLC (1.07M shares), and ArrowMark Colorado Holdings LLC (1.03M shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.